Calithera Biosciences, Inc. financial data

Symbol
CALA on OTC
Industry
Pharmaceutical Preparations
Location
343 Oyster Point Blvd #200, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2022 - Mar 31, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 410 % -36.6%
Debt-to-equity 53.2 % +121%
Return On Equity -201 % -13.5%
Return On Assets -98.2 % +22.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.87M shares -93.8%
Common Stock, Shares, Outstanding 4.87M shares +26.2%
Entity Public Float 11.5M USD -92%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 4.87M shares +31.3%
Weighted Average Number of Shares Outstanding, Diluted 4.87M shares +31.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.45M USD -44.2%
General and Administrative Expense 13.5M USD -35.1%
Operating Income (Loss) -42.1M USD +63.6%
Net Income (Loss) Attributable to Parent -39.7M USD +65.5%
Earnings Per Share, Basic -2.01 USD/shares +33.2%
Earnings Per Share, Diluted -2.01 USD/shares +33.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.5M USD -57.3%
Assets, Current 26.6M USD -56.7%
Property, Plant and Equipment, Net 434K USD -21.9%
Operating Lease, Right-of-Use Asset 1.35M USD -45.6%
Assets 28.7M USD -55.7%
Accounts Payable, Current 732K USD -79.9%
Employee-related Liabilities, Current 1.79M USD -45.4%
Liabilities, Current 7.39M USD -47.2%
Operating Lease, Liability, Noncurrent 136K USD -91.8%
Liabilities 8.28M USD -47.1%
Retained Earnings (Accumulated Deficit) -513M USD -4.33%
Stockholders' Equity Attributable to Parent 20.4M USD +143%
Liabilities and Equity 28.7M USD -55.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16M USD +27.2%
Net Cash Provided by (Used in) Financing Activities 1.14M USD -88.1%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 4.87M shares +26.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.9M USD -149%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.7M USD -57%
Deferred Tax Assets, Valuation Allowance 125M USD +7.84%
Deferred Tax Assets, Gross 125M USD +7.6%
Operating Lease, Liability 1.67M USD -45.2%
Depreciation 64K USD -12.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39.7M USD +65.5%
Lessee, Operating Lease, Liability, to be Paid 1.73M USD -47.2%
Property, Plant and Equipment, Gross 3.97M USD +3.04%
Operating Lease, Liability, Current 1.53M USD +11.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 136K USD -91.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.59M USD +3.04%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 63K USD -73.2%
Deferred Tax Assets, Operating Loss Carryforwards 89.4M USD +4.64%
Preferred Stock, Shares Issued 1M shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 9.1M USD +8.36%
Operating Lease, Payments 1.5M USD 0%
Preferred Stock, Shares Outstanding 1M shares
Deferred Tax Assets, Net of Valuation Allowance 283K USD -45.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%